

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/986,625	11/09/2001	Gregory A. Hair	8636.0001-02	5944
22852	7590 09/15/2003			
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			EXAMINER	
LLP			STRZELECKA, TERESA E	
1300 I STREE	T, NW DN, DC 20005			
WASHINGIC	JN, DC 20003		ART UNIT	PAPER NUMBER
			1637	
			DATE MAILED: 09/15/2003	
				G
				- 1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/986,625	HAIR ET AL.			
Office Action Summary	Examiner	Art Unit			
	Teresa E Strzelecka	1637			
The MAILING DATE of this communication app					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 2 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on 21 A	pril 2003 .				
2a) ☐ This action is FINAL . 2b) ☐ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>49-63</u> is/are pending in the application.					
4a) Of the above claim(s) <u>60</u> is/are withdrawn from consideration.					
5)⊠ Claim(s) <u>49-59 and 61-63</u> is/are allowed.					
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	· - · ·				
11) The proposed drawing correction filed on		• •			
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3.	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/986,625

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

- 1. Applicant's election with traverse of Group III (claims 49-63, SEQ ID NO: 33, species of claim 59) in Paper No. 8 is acknowledged. The traversal is on the ground(s) that a nucleic acid with SEQ ID NO: 33 is a species of a nucleic acid with SEQ ID NO: 22, and the protein with amino acid sequence of SEQ ID NO: 34 encoded by SEQ ID NO: 33 is a species of a protein with amino acid sequence of SEQ ID NO: 10 (claim 58) encoded by SEQ ID NO: 22. This is found persuasive, and claims 49-63 will be examined with respect to SEQ ID NO: 22 and 33, with the species of claims 58 and 59.
- 2. Claim 60 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 8.

Information Disclosure Statement

3. The information disclosure statement (IDS) submitted on August 6, 2002 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Priority

4. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification of in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)). The specific reference to any prior nonprovisional application must include the relationship (i.e., continuation, divisional, or

continuation-in-part) between the applications except when the reference is to a prior application of a CPA assigned the same application number.

Allowable Subject Matter

5. The following is an examiner's statement of reasons for allowance: Applicants' invention is a method of inducing bone formation, the method comprising transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein, wherein the nucleic acid molecule is SEQ ID NO: 22 or SEQ ID NO: 33.

No references were found teaching or suggesting SEQ ID NO: 22 or SEQ ID NO: 33.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

6. Claims 49-59 and 61-63 are allowed with respect to nucleic acids with SEQ ID NO: 22 and 33.

Conclusion

- 7. This application is in condition for allowance except for the following formal matters:
 - a) cancellation of SEQ ID NO: 2 from claims 49 and 63,
 - b) cancellation of claim 60,
- c) amendment to the first paragraph of the specification to include reference to parent applications.

Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Application/Control Number: 09/986,625 Page 4

Art Unit: 1637

A shortened statutory period for reply to this action is set to expire **TWO MONTHS** from the mailing date of this letter.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (703) 306-5877. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

TS September 10, 2003

> JEFFREY FREDMAN PRIMARY EXAMINER